Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Prevalence of human papillomavirus, human immunodeficiency virus and other sexually transmitted infections among female sex workers in Togo: a national cross-sectional survey.

Ferré VM, Ekouevi DK, Gbeasor-Komlanvi FA, Collin G, Le Hingrat Q, Tchounga B, Salou M, Descamps D, Charpentier C, Dagnra AC.

Clin Microbiol Infect. 2019 Apr 30. pii: S1198-743X(19)30191-0. doi: 10.1016/j.cmi.2019.04.015. [Epub ahead of print]

PMID:
31051265
2.

Resistance to integrase inhibitors: a national study in HIV-1-infected treatment-naive and -experienced patients.

Marcelin AG, Grude M, Charpentier C, Bellecave P, Le Guen L, Pallier C, Raymond S, Mirand A, Bocket L, Fofana DB, Delaugerre C, Nguyen T, Montès B, Jeulin H, Mourez T, Fafi-Kremer S, Amiel C, Roussel C, Dina J, Trabaud MA, Le Guillou-Guillemette H, Vallet S, Signori-Schmuck A, Maillard A, Ferre V, Descamps D, Calvez V, Flandre P; ANRS AC43 Resistance Group.

J Antimicrob Chemother. 2019 May 1;74(5):1368-1375. doi: 10.1093/jac/dkz021.

PMID:
30789205
3.

Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France.

Assoumou L, Bocket L, Pallier C, Grude M, Ait-Namane R, Izopet J, Raymond S, Charpentier C, Visseaux B, Wirden M, Trabaud MA, Le Guillou-Guillemette H, Allaoui C, Henquell C, Krivine A, Dos Santos G, Delamare C, Bouvier-Alias M, Montes B, Ferre V, De Monte A, Signori-Schmuck A, Maillard A, Morand-Joubert L, Tumiotto C, Fafi-Kremer S, Amiel C, Barin F, Marque-Juillet S, Courdavault L, Vallet S, Beby-Defaux A, de Rougemont A, Fenaux H, Avettand-Fenoel V, Allardet-Servent A, Plantier JC, Peytavin G, Calvez V, Chaix ML, Descamps D; ANRS AC-43 Resistance Study Group.

J Antimicrob Chemother. 2019 May 1;74(5):1417-1424. doi: 10.1093/jac/dkz011.

PMID:
30753724
4.

Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey.

Ferré VM, Gbeasor-Komlanvi FA, Collin G, Dagnra AC, Le Hingrat Q, Jaquet A, Salou M, Descamps D, Charpentier C, Ekouevi DK.

Clin Infect Dis. 2019 Aug 30;69(6):1019-1026. doi: 10.1093/cid/ciy1012.

PMID:
30520971
5.

Presence of Human Papillomavirus (HPV) Apolipoprotein B Messenger RNA Editing, Catalytic Polypeptide-Like 3 (APOBEC)-Related Minority Variants in HPV-16 Genomes From Anal and Cervical Samples but Not in HPV-52 and HPV-58.

Mariaggi AA, Péré H, Perrier M, Visseaux B, Collin G, Veyer D, Le Hingrat Q, Ferré VM, Joly V, Couvelard A, Bucau M, Davitian C, Descamps D, Abramowitz L, Charpentier C.

J Infect Dis. 2018 Aug 24;218(7):1027-1036. doi: 10.1093/infdis/jiy287.

PMID:
29788374
6.

In vivo and ex vivo analyses of amyloid toxicity in the Tc1 mouse model of Down syndrome.

Naert G, Ferré V, Keller E, Slender A, Gibbins D, Fisher EM, Tybulewicz VL, Maurice T.

J Psychopharmacol. 2018 Feb;32(2):174-190. doi: 10.1177/0269881117743484. Epub 2017 Dec 7.

7.

Interest of proviral HIV-1 DNA genotypic resistance testing in virologically suppressed patients candidate for maintenance therapy.

Allavena C, Rodallec A, Leplat A, Hall N, Luco C, Le Guen L, Bernaud C, Bouchez S, André-Garnier E, Boutoille D, Ferré V, Raffi F.

J Virol Methods. 2018 Jan;251:106-110. doi: 10.1016/j.jviromet.2017.10.016. Epub 2017 Oct 16.

PMID:
29042218
8.

An NS5A single optimized method to determine genotype, subtype and resistance profiles of Hepatitis C strains.

Andre-Garnier E, Besse B, Rodallec A, Ribeyrol O, Ferre V, Luco C, Le Guen L, Bourgeois N, Gournay J, Billaud E, Raffi F, Coste-Burel M, Imbert-Marcille BM.

PLoS One. 2017 Jul 20;12(7):e0179562. doi: 10.1371/journal.pone.0179562. eCollection 2017.

9.

Antiretroviral-treated HIV-1 patients can harbour resistant viruses in CSF despite an undetectable viral load in plasma.

Soulie C, Grudé M, Descamps D, Amiel C, Morand-Joubert L, Raymond S, Pallier C, Bellecave P, Reigadas S, Trabaud MA, Delaugerre C, Montes B, Barin F, Ferré V, Jeulin H, Alloui C, Yerly S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS AC11 Resistance Study Group.

J Antimicrob Chemother. 2017 Aug 1;72(8):2351-2354. doi: 10.1093/jac/dkx128.

PMID:
28472307
10.

Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL: a 2014 French nationwide study.

Assoumou L, Charpentier C, Recordon-Pinson P, Grudé M, Pallier C, Morand-Joubert L, Fafi-Kremer S, Krivine A, Montes B, Ferré V, Bouvier-Alias M, Plantier JC, Izopet J, Trabaud MA, Yerly S, Dufayard J, Alloui C, Courdavault L, Le Guillou-Guillemette H, Maillard A, Amiel C, Vabret A, Roussel C, Vallet S, Guinard J, Mirand A, Beby-Defaux A, Barin F, Allardet-Servent A, Ait-Namane R, Wirden M, Delaugerre C, Calvez V, Chaix ML, Descamps D, Reigadas S; ANRS AC-11 Resistance Study Group.

J Antimicrob Chemother. 2017 Jun 1;72(6):1769-1773. doi: 10.1093/jac/dkx042.

PMID:
28333232
11.

Leucettine L41, a DYRK1A-preferential DYRKs/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Aβ25-35 peptide administration in mice.

Naert G, Ferré V, Meunier J, Keller E, Malmström S, Givalois L, Carreaux F, Bazureau JP, Maurice T.

Eur Neuropsychopharmacol. 2015 Nov;25(11):2170-82. doi: 10.1016/j.euroneuro.2015.03.018. Epub 2015 Apr 10.

PMID:
26381812
12.

Mathematical Modeling of HIV Dynamics After Antiretroviral Therapy Initiation: A Review.

Rivadeneira PS, Moog CH, Stan GB, Brunet C, Raffi F, Ferré V, Costanza V, Mhawej MJ, Biafore F, Ouattara DA, Ernst D, Fonteneau R, Xia X.

Biores Open Access. 2014 Oct 1;3(5):233-41. doi: 10.1089/biores.2014.0024. Review.

13.

Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma.

Soulie C, Descamps D, Grudé M, Schneider V, Trabaud MA, Morand-Joubert L, Delaugerre C, Montes B, Barin F, Ferre V, Raymond S, Jeulin H, Alloui C, Yerly S, Pallier C, Reigadas S, Signori-Schmuck A, Guigon A, Fafi-Kremer S, Haïm-Boukobza S, Mirand A, Maillard A, Vallet S, Roussel C, Assoumou L, Calvez V, Flandre P, Marcelin AG; ANRS Resistance AC11 Group.

J Antimicrob Chemother. 2015 Feb;70(2):566-72. doi: 10.1093/jac/dku419. Epub 2014 Oct 25.

PMID:
25344810
14.

Mathematical modeling of HIV dynamics after antiretroviral therapy initiation: a clinical research study.

Rivadeneira PS, Moog CH, Stan GB, Costanza V, Brunet C, Raffi F, Ferré V, Mhawej MJ, Biafore F, Ouattara DA, Ernst D, Fonteneau R, Xia X.

AIDS Res Hum Retroviruses. 2014 Sep;30(9):831-4. doi: 10.1089/AID.2013.0286. No abstract available.

15.

Nevirapine-raltegravir combination, an NRTI and PI/r sparing regimen, as maintenance antiretroviral therapy in virologically suppressed HIV-1-infected patients.

Reliquet V, Chirouze C, Allavena C, Muret P, Peytavin G, André-Garnier E, Bettinger D, Ferré V, Hoen B, Raffi F.

Antivir Ther. 2014;19(1):117-23. doi: 10.3851/IMP2691. Epub 2013 Oct 22.

PMID:
24145365
16.

Residual viremia in patients on antiretroviral therapy incorporating nevirapine is not associated with the gag-specific cellular immune response.

McIlroy D, Allavena C, Rodallec A, Billaud E, Ferré V, Raffi F.

J Med Virol. 2014 Jun;86(6):1087-92. doi: 10.1002/jmv.23743. Epub 2013 Sep 23.

PMID:
24114722
17.

Evaluation of residual viremia and quantitation of soluble CD14 in a large cohort of HIV-infected adults on a long-term non-nucleoside reverse transcriptase inhibitor-based regimen.

Allavena C, Rodallec A, Sécher S, Reliquet V, Baffoin S, André-Garnier E, Billaud E, Raffi F, Ferré V.

J Med Virol. 2013 Nov;85(11):1878-82. doi: 10.1002/jmv.23679. Epub 2013 Jul 16.

PMID:
23861166
18.

Algorithm-based prediction of HIV-1 subtype D coreceptor use.

Dina J, Raymond S, Maillard A, Le Guillou-Guillemette H, Rodalec A, Beby-Defaux A, Giraudeau G, Vallet S, Mourez T, Payan C, Vabret A, Ruffault A, Ferre V, Izopet J, Plantier JC.

J Clin Microbiol. 2013 Sep;51(9):3087-9. doi: 10.1128/JCM.00798-13. Epub 2013 Jun 26.

19.

Seroprevalence and Molecular Characterisation of Human Hepatitis A virus in Serum Samples of Tunisian Patients with Clinical Symptoms of Viral Hepatitis.

Gharbi-Khelifi H, Abid NB, Beji A, Bhiri L, Harrath R, Sdiri K, Billaudel S, Ferre V, Aouni M.

Indian J Virol. 2012 Jun;23(1):29-35. doi: 10.1007/s13337-012-0063-6. Epub 2012 Mar 25.

20.

A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.

Marcelin AG, Delaugerre C, Beaudoux C, Descamps D, Morand-Joubert L, Amiel C, Schneider V, Ferre V, Izopet J, Si-Mohamed A, Maillard A, Henquell C, Desbois D, Lazrek M, Signori-Schmuck A, Rogez S, Yerly S, Trabaud MA, Plantier JC, Fourati S, Houssaini A, Masquelier B, Calvez V, Flandre P; ANRS AC11 Resistance Group.

Int J Antimicrob Agents. 2013 Jul;42(1):42-7. doi: 10.1016/j.ijantimicag.2013.02.016. Epub 2013 Apr 4.

PMID:
23562640
21.

Impact of lopinavir/ritonavir use on antiretroviral resistance in recent clinical practice.

Lambert-Niclot S, Masquelier B, Cohen Codar I, Soulie C, Delaugerre C, Morand-Joubert L, Charpentier C, Ferre V, Plantier JC, Montes B, Carret S, Perrot V, Peytavin G, Costagliola D, Calvez V, Marcelin AG; EOLE Study Group.

J Antimicrob Chemother. 2012 Oct;67(10):2487-93. Epub 2012 Jun 25.

PMID:
22733652
22.

Characterization of outbreak hepatitis a isolates in five Tunisian childcare centers.

Gharbi-Khelifi H, Ben Salem Abid N, Sdiri K, Harrath R, Beji A, Bhiri L, Billaudel S, Ferre V, Aouni M.

Braz J Microbiol. 2011 Jul;42(3):1204-12. doi: 10.1590/S1517-838220110003000046. Epub 2011 Sep 1.

23.

Despite an impaired response to IL-7, CD4+EM T cells from HIV-positive patients proliferate normally in response to IL-15 and its superagonist, RLI.

Pacheco Y, Solé V, Billaud E, Allavena C, Plet A, Ferré V, Garrigue-Antar L, Raffi F, Jacques Y, McIlroy D.

AIDS. 2011 Sep 10;25(14):1701-10. doi: 10.1097/QAD.0b013e328349a437.

PMID:
21673554
24.

Virological response to darunavir in patients infected with HIV is linked to darunavir resistance-associated mutations corrected by the count of mutations with positive impact and is not associated with pharmacological and combined virological/pharmacological parameters.

Dailly E, Rodallec A, Allavena C, Deslandes G, Garnier E, Billaud E, Ferré V, Reliquet V, Bouquié R, Raffi F, Jolliet P.

Fundam Clin Pharmacol. 2012 Aug;26(4):538-42. doi: 10.1111/j.1472-8206.2011.00949.x. Epub 2011 May 5.

PMID:
21545648
25.

The immune response to the RT181-189 epitope in HIV-1-infected patients is associated with viral sequence polymorphism flanking the epitope.

Pacheco Y, Allavena C, Guilloux Y, Mueller-Schmucker SM, Hueckelhoven AG, André-Garnier E, Cleon F, Ferré V, Rodallec A, Billaud E, Harrer T, Raffi F, McIlroy D.

J Clin Immunol. 2011 Aug;31(4):681-9. doi: 10.1007/s10875-011-9520-z. Epub 2011 Apr 14.

PMID:
21491096
26.

Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.

Recordon-Pinson P, Soulié C, Flandre P, Descamps D, Lazrek M, Charpentier C, Montes B, Trabaud MA, Cottalorda J, Schneider V, Morand-Joubert L, Tamalet C, Desbois D, Macé M, Ferré V, Vabret A, Ruffault A, Pallier C, Raymond S, Izopet J, Reynes J, Marcelin AG, Masquelier B; ANRS AC11 Resistance Study Group.

Antimicrob Agents Chemother. 2010 Aug;54(8):3335-40. doi: 10.1128/AAC.00148-10. Epub 2010 Jun 7.

27.

Long term oncostatin M treatment induces an osteocyte-like differentiation on osteosarcoma and calvaria cells.

Brounais B, David E, Chipoy C, Trichet V, Ferré V, Charrier C, Duplomb L, Berreur M, Rédini F, Heymann D, Blanchard F.

Bone. 2009 May;44(5):830-9. doi: 10.1016/j.bone.2008.12.021. Epub 2009 Jan 3.

PMID:
19168167
28.

Cellular normalization of viral DNA loads on whole blood improves the clinical management of cytomegalovirus or Epstein Barr virus infections in the setting of pre-emptive therapy.

Bressollette-Bodin C, Coste-Burel M, Besse B, André-Garnier E, Ferre V, Imbert-Marcille BM.

J Med Virol. 2009 Jan;81(1):90-8. doi: 10.1002/jmv.21334.

PMID:
19031462
29.

HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide.

Descamps D, Assoumou L, Masquelier B, Marcelin AG, Saidi S, Tamalet C, Cottalorda J, Plantier JC, Montes B, Izopet J, Peytavin G, Yerly S, Schneider V, Delaugerre C, Ferré V, Ruffault A, Pallier C, Morand-Joubert L, Chaix ML, Calvez V, Brun-Vézinet F, Costagliola D; ANRS AC-11 Resistance Study Group.

J Antimicrob Chemother. 2008 Sep;62(3):451-5. doi: 10.1093/jac/dkn225. Epub 2008 Jun 13.

PMID:
18552344
30.

Detection and quantification by real-time RT-PCR of hepatitis A virus from inoculated tap waters, salad vegetables, and soft fruits: characterization of the method performances.

Dubois E, Hennechart C, Merle G, Burger C, Hmila N, Ruelle S, Perelle S, Ferré V.

Int J Food Microbiol. 2007 Jun 30;117(2):141-9. Epub 2007 Mar 30.

PMID:
17490771
31.

Genetic analysis of HAV strains in Tunisia reveals two new antigenic variants.

Gharbi-Khelifi H, Sdiri K, Harrath R, Fki L, Hakim H, Berthomé M, Billaudel S, Ferre V, Aouni M.

Virus Genes. 2007 Oct;35(2):155-9. Epub 2007 Mar 29.

PMID:
17393293
32.

Constant mitochondrial DNA levels in blood leukocytes of patients enrolled in a NRTI-free therapeutic trial (BIKS-2 study).

Amellal B, Allavena C, André-Garnier E, Ferré V, Valantin MA, Delfraissy JF, Lafeuillade A, Bonmarchand M, Calvez V, Raffi F.

J Infect. 2007 Jun;54(6):603-8. Epub 2007 Jan 4.

PMID:
17207857
33.

A 1-year study of the epidemiology of hepatitis A virus in Tunisia.

Gharbi-Khelifi H, Sdiri K, Ferre V, Harrath R, Berthome M, Billaudel S, Aouni M.

Clin Microbiol Infect. 2007 Jan;13(1):25-32.

34.

Generation of llama single-domain antibodies against methotrexate, a prototypical hapten.

Alvarez-Rueda N, Behar G, Ferré V, Pugnière M, Roquet F, Gastinel L, Jacquot C, Aubry J, Baty D, Barbet J, Birklé S.

Mol Immunol. 2007 Mar;44(7):1680-90. Epub 2006 Sep 29.

PMID:
17011035
35.

Hepatitis A in Tunisia: phylogenetic analysis of hepatitis A virus from 2001 to 2004.

Gharbi-Khelifi H, Ferre V, Sdiri K, Berthome M, Fki L, Harrath R, Billaudel S, Aouni M.

J Virol Methods. 2006 Dec;138(1-2):109-16. Epub 2006 Sep 26.

PMID:
17005259
36.

Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables.

Dubois E, Hennechart C, Deboosère N, Merle G, Legeay O, Burger C, Le Calvé M, Lombard B, Ferré V, Traoré O.

Int J Food Microbiol. 2006 Apr 25;108(2):164-71. Epub 2006 Jan 4.

PMID:
16387377
37.

Decrease of enteric micro-organisms from rural sewage sludge during their composting in straw mixture.

Pourcher AM, Morand P, Picard-Bonnaud F, Billaudel S, Monpoeho S, Federighi M, Ferré V, Moguedet G.

J Appl Microbiol. 2005;99(3):528-39.

38.

Stavudine, didanosine and nevirapine in antiretroviral-naive HIV-1-infected patients.

Reliquet V, Ferré V, Hascoet C, Besnier JM, Bellein V, Arvieux C, Molina JM, Breux JP, Zucman D, Rozenbaum W, Allavena C, Raffi F; VIRGO Study Team.

Antivir Ther. 1999;4 Suppl 3:83-4.

PMID:
16021876
39.

Salvage therapy with ritonavir-boosted amprenavir/fosamprenavir: virological and immunological response in two years follow-up.

Quercia R, Garnier E, Ferré V, Morineau P, Bonnet B, Soulard C, Raffi F.

HIV Clin Trials. 2005 Mar-Apr;6(2):73-80.

PMID:
15983891
40.

Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients.

Allavena C, Ferré V, Brunet-François C, Delfraissy JF, Lafeuillade A, Valantin MA, Bentata M, Michelet C, Poizot-Martin I, Dailly E, Launay O, Raffi F; Bitherapy Kaletra-Sustiva Study Group.

J Acquir Immune Defic Syndr. 2005 Jul 1;39(3):300-6.

PMID:
15980689
41.

Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma.

de Mendoza C, Koppelman M, Montès B, Ferre V, Soriano V, Cuypers H, Segondy M, Oosterlaken T.

J Virol Methods. 2005 Jul;127(1):54-9. Epub 2005 Apr 25.

PMID:
15893566
42.

Clearance of human-pathogenic viruses from sludge: study of four stabilization processes by real-time reverse transcription-PCR and cell culture.

Monpoeho S, Maul A, Bonnin C, Patria L, Ranarijaona S, Billaudel S, Ferré V.

Appl Environ Microbiol. 2004 Sep;70(9):5434-40.

43.

Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.

Masquelier B, Tamalet C, Montès B, Descamps D, Peytavin G, Bocket L, Wirden M, Izopet J, Schneider V, Ferré V, Ruffault A, Palmer P, Trylesinski A, Miller M, Brun-Vézinet F, Costagliola D; ANRS AC11 Resistance study group.

Antivir Ther. 2004 Jun;9(3):315-23.

PMID:
15259894
44.

Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O.

Gueudin M, Lemée V, Ferre V, Beby-Defaux A, Pathé JP, Guist'hau O, Braun J, Simon F, Plantier JC.

J Acquir Immune Defic Syndr. 2004 May 1;36(1):639-41. No abstract available.

PMID:
15097309
45.

Quantification of human astroviruses in sewage using real-time RT-PCR.

Le Cann P, Ranarijaona S, Monpoeho S, Le Guyader F, Ferré V.

Res Microbiol. 2004 Jan-Feb;155(1):11-5.

PMID:
14759703
46.

Genetic variability of hepatitis A virus.

Costa-Mattioli M, Di Napoli A, Ferré V, Billaudel S, Perez-Bercoff R, Cristina J.

J Gen Virol. 2003 Dec;84(Pt 12):3191-201. Review.

PMID:
14645901
47.

R57K polymorphism in the human immunodeficiency virus type 1 protease as predictor of early virological failure in a cohort of antiretroviral-naive patients treated mostly with a nelfinavir-containing regimen.

Masquelier B, Droz C, Dary M, Perronne C, Ferré V, Spire B, Descamps D, Raffi F, Brun-Vézinet F, Chêne G; APROCO/COPILOTE Study Group.

Antimicrob Agents Chemother. 2003 Nov;47(11):3623-6.

48.

Viral and clinical factors associated with the fulminant course of hepatitis A infection.

Rezende G, Roque-Afonso AM, Samuel D, Gigou M, Nicand E, Ferre V, Dussaix E, Bismuth H, Féray C.

Hepatology. 2003 Sep;38(3):613-8.

PMID:
12939587
49.

Evidence of recombination in natural populations of hepatitis A virus.

Costa-Mattioli M, Ferré V, Casane D, Perez-Bercoff R, Coste-Burel M, Imbert-Marcille BM, Andre EC, Bressollette-Bodin C, Billaudel S, Cristina J.

Virology. 2003 Jun 20;311(1):51-9.

50.

Prolonged hepatitis A infection in an HIV-1 seropositive patient.

Costa-Mattioli M, Allavena C, Poirier AS, Billaudel S, Raffi F, Ferré V.

J Med Virol. 2002 Sep;68(1):7-11.

PMID:
12210424

Supplemental Content

Support Center